12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO, CA
2026 Annual Meeting Results: Directors Elected and Compensation Approved
Investor Presentation
Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment.
Reports First Quarter 2026 Results and Provides Business Update
Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Annual Report to Security Holders
Amended material disclosure
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence